Pharmaceutical Products

VANIQA® is the only prescription product available in the U.S. for the reduction of growth of unwanted facial hair in women. VANIQA works during the growth phase of the hair cycle by blocking an enzyme that is necessary for hair growth. VANIQA does not remove facial hair; instead, it is designed to reduce the rate of growth of facial hair and increase the interval between periods of hair removal when used together with traditional hair removal methods such as shaving, waxing and tweezing. Clinical trials have shown results from the use of VANIQA in four to eight weeks from initial application, with continued improvement over time.

If no improvement is seen after 6 months of use, VANIQA should be discontinued. The most frequent adverse events related to treatment with VANIQA were skin related adverse events. Individual results may vary. Please see full prescribing information for VANIQA.

EpiQuin® Micro is a topical 4% hydroquinone product indicated for the treatment of hyperpigmentation, a condition that results in heavily pigmented or dark areas of the skin. EpiQuin Micro is the only prescription hydroquinone product available with the MICROSPONGE® delivery system. The unique formulation allows for a gradual release of the active ingredient, prolonging exposure to the treatment while minimizing skin irritation.

EpiQuin Micro should be tested for skin sensitivity prior to use. Excessive inflammatory responses are contraindications to further use, while minor redness is not. Hydroquinone may produce unwanted effects if not used as directed. Please see full prescribing information for EpiQuin Micro. MICROSPONGE® is a registered trademark of AMCOL International Corporation.